Stockscreener 앱 받기
1.68
16.00%
-0.32
전일 마감가:
$2.00
열려 있는:
$1.88
하루 거래량:
666.72K
Relative Volume:
7.39
시가총액:
$13.55M
수익:
$149.50K
순이익/손실:
$-6.96M
주가수익비율:
-1.2353
EPS:
-1.36
순현금흐름:
$-6.37M
1주 성능:
-6.93%
1개월 성능:
-2.00%
6개월 성능:
+15.86%
1년 성능:
-13.85%
1일 변동 폭
$1.65
$1.89
1주일 범위
$1.65
$2.045
52주 변동 폭
$1.21
$2.55
Biorestorative Therapies Inc Stock (BRTX) Company Profile
명칭
Biorestorative Therapies Inc
전화
(631) 760-8100
주소
40 MARCUS DRIVE, MELVILLE
BRTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BRTX
Biorestorative Therapies Inc
|
1.68 | 13.55M | 149.50K | -6.96M | -6.37M | -1.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Biorestorative Therapies Inc 주식(BRTX)의 최신 뉴스
BioRestorative Therapies (BRTX) Reports Promising Phase 2 Trial - GuruFocus
Anchoring Your Portfolio: Is BRTX Stock a Safe Harbor? - investchronicle.com
BioRestorative Reports Promising Phase 2 Trial Results - TipRanks
BioRestorative Therapies Says BRTX-100 Improved Function in Phase 2 Chronic Lumbar Disc Disease Trial - marketscreener.com
BioRestorative Reports Compelling Preliminary Data For FDA-Fast-Tracked BRTX-100 - marketscreener.com
BioRestorative reports positive data from BRTX-100 stem cell therapy trial - Investing.com India
BioRestorative Therapies, Inc. Reports Promising Phase 2 Clinical Trial Results for BRTX-100 at ISSCR 2025 Annual Meeting - Nasdaq
Breakthrough Stem Cell Therapy BRTX-100 Achieves 74% Success Rate in Chronic Back Pain Trial - Stock Titan
Citadel Advisors LLC Buys New Stake in BioRestorative Therapies, Inc. (NASDAQ:BRTX) - Defense World
BioRestorative Therapies (OTCMKTS:BRTXQ) Trading 0.3% Higher – Still a Buy? - Defense World
Stocks in play: ATCO Ltd. - The Globe and Mail
BioRestorative Welcomes Serial Regenerative Medicine Entrepreneur, Company Builder and Leader, Sandy Lipkins, to BRTX Team - Barchart.com
BRTX Appoints Sandy Lipkins for Strategic Expansion | BRTX Stock News - GuruFocus
30-Year Regenerative Medicine Pioneer Joins BioRestorative to Lead Global Commercialization Strategy - Stock Titan
BioRestorative Therapies (NASDAQ:BRTX) Shares Up 0.3% – Should You Buy? - Defense World
BioRestorative to Present Major Update on Promising Preliminary Phase 2 BRTX-100 Data at ISSCR 2025 - The Globe and Mail
BioRestorative Therapies to Present New Preliminary Clinical Data for BRTX-100 at ISSCR 2025 Annual Meeting - Nasdaq
Major Phase 2 Clinical Trial Update: BRTX-100 Stem Cell Therapy Shows New Safety Data in 30 Back Pain Patients - Stock Titan
BioRestorative Therapies Announces Closing of $23 Million Public Offering - The Globe and Mail
BioRestorative Therapies (OTCMKTS:BRTXQ) Shares Down 3.6% – Should You Sell? - Defense World
What is Roth Capital’s Estimate for BRTX Q2 Earnings? - Defense World
BioRestorative Therapies, Inc. (NASDAQ:BRTX) Q1 2025 Earnings Call Transcript - Insider Monkey
BioRestorative Therapies’ Earnings Call: Progress Amid Challenges - TipRanks
Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Lags Revenue Estimates - MSN
BioRestorative Therapies Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings call transcript: BioRestorative Therapies Q1 2025 sees widened losses - Investing.com Nigeria
BioRestorative Therapies Reports Q1 2025 Results and Updates - TipRanks
BIORESTORATIVE THERAPIES Earnings Results: $BRTX Reports Quarterly Earnings - Nasdaq
BioRestorative Therapies Reports First Quarter 2025 Financial Results and Provides Business Update - Ortho Spine News
BioRestorative's Spine Treatment Gets FDA Fast Track After Positive 52-Week Trial Data - Stock Titan
BioRestorative Therapies (BRTX) Reports Positive Initial Results in Phase 2 Trial | BRTX Stock News - GuruFocus
Phase 2 Trial of BRTX-100 in cLDD Continues to Generate Positive Preliminary Blinded Data - Ortho Spine News
BioRestorative Therapies, Inc. Announces Positive Preliminary Data from Phase 2 Trial of BRTX-100 for Chronic Lumbar Disc Disease at ISCT 2025 Annual Meeting - Nasdaq
BioRestorative Therapies (BRTX) to Release Quarterly Earnings on Wednesday - Defense World
BioRestorative Therapies Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView
BioRestorative Therapies to Report First Quarter 2025 Financial Results and Host Conference Call on May 14, 2025 - The Manila Times
BioRestorative Therapies, Inc. to Release First Quarter 2025 Financial Results on May 14, 2025 - Nasdaq
BioRestorative to Present a BRTX-100 Clinical Update at ISCT 2025 - The Manila Times
BioRestorative To Present A BRTX-100 Clinical Update At ISCT 2025 - Barchart.com
Reviewing BioRestorative Therapies (OTCMKTS:BRTX) and Silence Therapeutics (OTCMKTS:SLNCF) - Defense World
BioRestorative Therapies (OTCMKTS:BRTXQ) Trading Down 2.3% – Here’s Why - Defense World
Leveraging Stem Cells To Fight Chronic Lower Back Pain And Obesity With BioRestorative Therapies - The Globe and Mail
EQS-News: Leveraging Stem Cells To Fight Chronic Lower Back Pain And Obesity With BioRestorative Therapies - markets.businessinsider.com
BioRestorative Therapies Receives FDA Fast Track Approval For BRTX-100 To Treat Chronic Lumbar Disc Disease - FinancialContent
BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Recent Achievements of Key Clinical & Regulatory Milestones, and Highlight Commercial Opportunities - TradingView
BioRestorative CEO Reveals Latest Clinical Breakthroughs and Market Expansion Plans - Stock Titan
BioRestorative unaffected by new U.S. tariffs, continues clinical trials - Investing.com South Africa
BioRestorative confirms no material impact from reciprocal tariffs - marketscreener.com
Biorestorative Therapies Inc (BRTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.91%
1.17%
자본화:
|
볼륨(24시간):